Following several years of significant divestments to streamline its portfolio and repay debt, Aspen Pharmacare is continuing to look at bringing products in via licensing agreements, including in Latin America, Africa, Australia and “diverse Sterile opportunities.”
After studying “what markets we are good at and…what can we deliver organically out of…what we bought,” Aspen was “in a great position,” not least with the infrastructure it had laid down and retained in markets including China